CD8A and metabolic dysfunction-associated steatohepatitis: To corroborate these data and to more specifically address the role of XCR1+ cDC1 cells we determined if AZD5069/anti-PD1 therapy of orthotopic NASH-HCC would be affected by anti-XCL1-mediated blockade of XCL1, a major chemokine involved in mediating cDC1 and CD8 T cell interactions (figure 4K).38 AZD5069/anti-PD1 therapy resulted in an increase in activated intratumoural XCR1+ cDC1 cells in line with observations in DEN/ALIOS mice, but with cDC1 activation being selectively suppressed on treatment with anti-XCL1 (online supplemental figure 5E, F).